Search

Your search keyword '"López‐Duarte, Mónica"' showing total 28 results
Start Over Author "López‐Duarte, Mónica"
28 results on '"López‐Duarte, Mónica"'

1. Haemoglobinopathies and other rare anemias in Spain: ten years of a nationwide registry (REHem-AR)

Author

Marco Sánchez, José Manuel, Bardón Cancho, Eduardo Jesús, Benéitez, David, Payán-Pernía, Salvador, Collado Gimbert, Anna, Ruiz-Llobet, Anna, Salinas, José Antonio, Sebastián, Elena, Argilés, Bienvenida, Bermúdez, Mar, Vázquez, María Ángeles, Ortega, María José, López Rubio, Montserrat, Gondra, Ainhoa, Uriz, José Javier, Morado, Marta, Coll, María Teresa, López Duarte, Mónica, Baro, María, Cervera, Áurea, Recasens, Valle, García Blanes, Carmen, del Carcavilla, María Pozo, Tallon, María, González Espín, Ana, Olteanu Olteanu, Filip Camil, González, Pablo, del Mañú Pereira, María Mar, and Cela, Elena

Published
2024
Full Text
View/download PDF

2. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Author

Ceolin, Valeria, Brivio, Erica, van Tinteren, Harm, Rheingold, Susan R., Leahy, Allison, Vormoor, Britta, O’Brien, Maureen M., Rubinstein, Jeremy D., Kalwak, Krzysztof, De Moerloose, Barbara, Jacoby, Elad, Bader, Peter, López-Duarte, Mónica, Goemans, Bianca F., Locatelli, Franco, Hoogerbrugge, Peter, Calkoen, Friso G., and Zwaan, Christian Michel

Published
2023
Full Text
View/download PDF

3. Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia

Author

Galán Gómez, Víctor, de la Fuente Regaño, Lydia, Rodríguez Villa, Antonia, Díaz de Heredia Rubio, Cristina, González Vicent, Marta, Badell Serra, Isabel, María Fernández, José, Isabel Pascual Martínez, Antonia, María Pérez Hurtado, José, López Duarte, Mónica, Soledad Maldonado Regalado, M., and Pérez-Martínez, Antonio

Published
2022
Full Text
View/download PDF

4. Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia

Author

Galán Gómez, Víctor, de la Fuente Regaño, Lydia, Rodríguez Villa, Antonia, Díaz de Heredia Rubio, Cristina, González Vicent, Marta, Badell Serra, Isabel, Fernández, José María, Pascual Martínez, Antonia Isabel, Pérez Hurtado, José María, López Duarte, Mónica, Maldonado Regalado, M. Soledad, and Pérez-Martínez, Antonio

Published
2022
Full Text
View/download PDF

6. Genotype-phenotype relationship in pyruvate kinase deficiency: baseline transfusion dependence and splenectomy response

Author

Martínez-Nieto, Jorge, primary, Molina-Pérez, Marta, additional, Salido-Fierez, Eduardo J., additional, Beneitez-Pastor, David, additional, de la O-Abío, María, additional, Hernández-Rodríguez, Inés, additional, Payant-Pernía, Salvador, additional, Pérez de Soto, Inmaculada, additional, del Orbe-Barreto, Rafael, additional, Sevilla, Julián, additional, Ruiz-Llobet, Anna, additional, Ordóñez-García, María, additional, González-Fernández, Fernando A., additional, Sánchez-Quintana, Ana, additional, González-Méndez, Hugo, additional, López-Duarte, Mónica, additional, Mendoza-Sánchez, María del C., additional, Senent, Leonor, additional, de la Iglesia, Silvia, additional, Gómez-Rojas, Sandra, additional, Tenorio, María, additional, Gómez-Álvarez, Miguel, additional, Ropero, Paloma, additional, Benavente, Celina, additional, Villegas, Ana, additional, and Morado-Arias, Marta, additional

Published
2023
Full Text
View/download PDF

7. Relación entre genotipo y fenotipo en el déficit de piruvato quinasa: dependencia transfusional basal y respuesta a la esplenectomía

Author

Martínez-Nieto, Jorge, primary, Molina-Pérez, Marta, additional, Salido-Fierez, Eduardo J., additional, Beneitez-Pastor, David, additional, de la O-Abío, María, additional, Hernández-Rodríguez, Inés, additional, Payant-Pernía, Salvador, additional, Pérez de Soto, Inmaculada, additional, del Orbe-Barreto, Rafael, additional, Sevilla, Julián, additional, Ruiz-Llobet, Anna, additional, Ordóñez-García, María, additional, González-Fernández, Fernando A., additional, Sánchez-Quintana, Ana, additional, González-Méndez, Hugo, additional, López-Duarte, Mónica, additional, Mendoza-Sánchez, María del C., additional, Senent, Leonor, additional, de la Iglesia, Silvia, additional, Gómez-Rojas, Sandra, additional, Tenorio, María, additional, Gómez-Álvarez, Miguel, additional, Ropero, Paloma, additional, Benavente, Celina, additional, Villegas, Ana, additional, and Morado-Arias, Marta, additional

Published
2023
Full Text
View/download PDF

8. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)

Author

Moreno, Celia, primary, Ramos-Elbal, Eduardo, additional, Velasco, Pablo, additional, Aguilar, Yurena, additional, Gonzáález Martínez, Berta, additional, Fuentes, Carolina, additional, Molinos, Águeda, additional, Guerra-García, Pilar, additional, Palomo, Pilar, additional, Verdu, Jaime, additional, Adán Pedroso, Rosa María, additional, Vagace, José Manuel, additional, López-Duarte, Mónica, additional, Regueiro, Alexandra, additional, Tasso, María, additional, Dapena, José Luis, additional, Salinas, José Antonio, additional, Navarro, Samuel, additional, Bautista, Francisco, additional, Lassaletta, Álvaro, additional, Lendínez, Francisco, additional, Rives, Susana, additional, Pascual, Antonia, additional, Rodríguez, Antonia, additional, Pérez-Hurtado, José María, additional, Fernández, José María, additional, Pérez-Martínez, Antonio, additional, González-Vicent, Marta, additional, Díaz de Heredia, Cristina, additional, and Fuster, José Luis, additional

Published
2023
Full Text
View/download PDF

10. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Author

Ceolin, Valeria, primary, Brivio, Erica, additional, van Tinteren, Harm, additional, Rheingold, Susan R., additional, Leahy, Allison, additional, Vormoor, Britta, additional, O’Brien, Maureen M., additional, Rubinstein, Jeremy D., additional, Kalwak, Krzysztof, additional, De Moerloose, Barbara, additional, Jacoby, Elad, additional, Bader, Peter, additional, López-Duarte, Mónica, additional, Goemans, Bianca F., additional, Locatelli, Franco, additional, Hoogerbrugge, Peter, additional, Calkoen, Friso G., additional, and Zwaan, Christian Michel, additional

Published
2022
Full Text
View/download PDF

11. Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

Author

Bastida, Jose Maria, Marín-Quílez, Ana, Zamora, Ana, Benito Sanchez, Maria Rocio, Rodriguez Alen, Agustín, Sevivas, Teresa, Gómez-González, Pedro Luis, Díaz-Ajenjo, Lorena, Butta, Nora, Campos, Rosa M., Escribano, Paola, Huertas-Aragoneses, Jorge, Lopez-Duarte, Monica, León, Antonio, Mompel, Angela, De Oña Navarrete, Raquel, Peláez-Pleguezuelos, Irene, Ramos-Ortega, Fernando Jesús, Sebastian, Elena, Serrano, Claudia, Sierra-Aisa, Cristina, Velasco, Pablo, Murillo, Laura, Vidal-Laso, Rosa, Nomdedeu, Meritxell, Esteve Reyner, Jordi, Hernández-Rivas, Jesús María, Rivera Pozo, Jose, and Lozano, Maria Luisa

Published
2023
Full Text
View/download PDF

12. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)

Author

Fuster, José Luis, Molinos-Quintana, A., Fuentes, Carolina, Fernández, José M., Velasco, Pablo, Pascua, Toñi, Rives, Susana, Dapena, José L., Sisinni, Luisa, López‐Godino, Oriana, Palomo, Pilar, Villa‐Alcázar, Marta, Bautista, Francisco, González‐Vicent, Marta, López‐Duarte, Mónica, García‐Morín, Marina, Ramos-Elbal, Eduardo, Ramírez, Manuel, Fuster, José Luis, Molinos-Quintana, A., Fuentes, Carolina, Fernández, José M., Velasco, Pablo, Pascua, Toñi, Rives, Susana, Dapena, José L., Sisinni, Luisa, López‐Godino, Oriana, Palomo, Pilar, Villa‐Alcázar, Marta, Bautista, Francisco, González‐Vicent, Marta, López‐Duarte, Mónica, García‐Morín, Marina, Ramos-Elbal, Eduardo, and Ramírez, Manuel

Abstract

Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.

Published
2020

14. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

Author

Rives, Susana, Estella, Jesús, Gómez, Pedro, López-Duarte, Mónica, de Miguel, Purificación García, Verdeguer, Amparo, Moreno, Maria José, Vivanco, José Luis, Couselo, José Miguel, Fernández-Delgado, Rafael, Maldonado, Marisol, Tasso, María, López-Ibor, Blanca, Lendínez, Francisco, López-Almaraz, Ricardo, Uriz, Javier, Melo, Montserrat, Fernández-Teijeiro, Ana, Rodríguez, Isidoro, and Badell, Isabel

Published
2011
Full Text
View/download PDF

15. Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Author

Yanez San Segundo, Lucrecia, primary, Fernandez Escalada, Noemi, additional, Bermúdez, Arancha, additional, Martín Sánchez, Guillermo, additional, García Avila, Sara, additional, López Duarte, Mónica, additional, Colorado, Mercedes, additional, Romon, Iñigo, additional, Richard, Carlos, additional, and Ocio, Enrique M., additional

Published
2019
Full Text
View/download PDF

16. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).

Author

Fuster, José L., Molinos‐Quintana, Agueda, Fuentes, Carolina, Fernández, José M., Velasco, Pablo, Pascual, Toñi, Rives, Susana, Dapena, José L., Sisinni, Luisa, López‐Godino, Oriana, Palomo, Pilar, Villa‐Alcázar, Marta, Bautista, Francisco, González‐Vicent, Marta, López‐Duarte, Mónica, García‐Morín, Marina, Ramos-Elbal, Eduardo, and Ramírez, Manuel

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, CHILDHOOD cancer, PEDIATRIC hematology, B cells
Abstract

Summary: Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Author

Fernández Martínez, Cristina, primary, Bermúdez, Arancha, additional, García Ávila, Sara, additional, San Pedro, Borja, additional, Cabero Martínez, Almudena, additional, Yáñez, Lucrecia, additional, López Duarte, Mónica, additional, Colorado, Mercedes, additional, González de Villambrosia, Sonia, additional, Mora, Joan Manuel, additional, Gonzalez Romero, Yolanda, additional, Gomez, David, additional, Fenandez Luis, Sara, additional, Ormazabal, Irati, additional, Insunza, Andrés, additional, Romon, Iñigo, additional, Arroyo, Jose Luis, additional, Conde, Eulogio, additional, and Richard, Carlos, additional

Published
2018
Full Text
View/download PDF

19. Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Author

Cabero Martínez, Almudena, Bermudez, Arancha, Yañez, Lucrecia, Insunza, Andrés, Colorado, Mercedes Araujo, Fernandez Martinez, Cristina, Martinez Callejo, Virginia, Bernal Del Castillo, Teresa, Sánchez Escamilla, Miriam, López Duarte, Mónica, Pérez Vázquez, German, Montes, Carmen, Conde, Eulogio, Gutiérrez, Maria Luisa, García Ávila, Sara, Celis, Mara, and Richard, Carlos

Published
2017
Full Text
View/download PDF

24. Secondary haematological dysplasia after CAR‐T‐cell therapy for acute lymphoblastic leukaemia in children.

Author

Theron, Alexandre, Alonso‐Saladrigues, Anna, Dapena, Jose‐Luis, López‐Duarte, Mónica, Diaz de Heredia, Cristina, Verdú‐Amorós, Jaime, Sarrate, Edurne, Esperanza‐Cebollada, Elena, Cuatrecasas, Esther, Andreu, Sandra, Conde, Nuria, Sanchez‐Sierra, Nazaret, Isola, Ignacio, Camós, Mireia, Torrebadell, Montse, Rives, Susana, and Català, Albert

Subjects
*HEMATOPOIETIC stem cell transplantation, *LYMPHOBLASTIC leukemia, *MYELODYSPLASTIC syndromes, *ACUTE leukemia, *CYTOPENIA
Abstract

Summary The use of CAR‐T is becoming more widespread in the treatment of haematological malignancies. In adults, secondary myelodysplastic syndromes (MDS) after CAR‐T have been described. However, there are currently no data on the risk of MDS following CAR‐T in children treated for acute lymphoblastic leukaemia (ALL). We studied all children treated with CAR‐T cells at Hospital Sant Joan de Déu in Barcelona and those with persistent cytopenias were evaluated at the cytological, cytogenetic, and molecular levels to look for MDS. A total of 106 patients received CAR‐T for ALL. Among 40 patients without early relapse or subsequent therapy after CAR‐T, four fulfilled the WHO criteria for myelodysplasia. These four patients had received a haematopoietic stem cell transplantation (HSCT) prior to CAR‐T and presented cytopenias with severe dysplastic changes in bone marrow after CAR‐T. One patient had clonal MDS with high‐risk cytogenetics arising from the host cells requiring a HSCT. Three patients had non‐progressive dysplasia arising from the donor cells. Two are alive in complete remission with stable cytopenias and one succumbed to ALL relapse. This is the first description of post‐CAR‐T MDS and haematological dysplasia in children and highlights the need to monitor children with persistent post‐CAR‐T cytopenias. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia

Author

Galán Gómez, Víctor, de la Fuente Regaño, Lydia, Rodríguez Villa, Antonia, Díaz de Heredia Rubio, Cristina, González Vicent, Marta, Badell Serra, Isabel, Fernández, José María, Pascual Martínez, Antonia Isabel, Pérez Hurtado, José María, López Duarte, Mónica, Maldonado Regalado, M. Soledad, and Pérez-Martínez, Antonio

Abstract

Los resultados de los pacientes con diagnóstico de leucemia linfoblástica aguda con cromosoma de Philadelphia (LLA-Ph) continúan siendo desfavorables comparados con los otros tipos de leucemias linfoblásticas agudas, pese a las mejoras en los tratamientos farmacológicos y los avances del trasplante de progenitores hematopoyéticos (TPH).

Published
2021
Full Text
View/download PDF

26. Deletion in the BCL11B Gene and Intellectual Developmental Disorder with Speech Delay, Dysmorphic Facies, and T-cell Abnormalities - a Case Report.

Author

Roa-Bautista A, López-Duarte M, Paz-Gandiaga N, San Segundo Arribas D, and Ocejo-Vinyals JG

Abstract

Herein we described a retrospective analysis of a 13-year-old female patient with facial dysmorphia and immune disorder caused by BCL11B gene mutation. The patient upon physical examination presented a particular face (thin eyebrows, small mandible, and widened eye distance), delayed language and motor development. Supplementary examination showed expansion of CD8+, absence of type 2 Innate Lymphoid Cells, increased IgG and altered distribution of T cells. Genetic testing revealed a heterozygous frameshift variation in exon 4 of the BCL11B gene; c.1887_c.1893delCGGCGGG (p.Gly630Glyfs*91). Finally, a BCL11B gene mutation could lead to abnormal development of the nervous and immune systems, therefore, it is necessary to consider this syndrome in patients with the clinical and immunological phenotype described below., (Copyright © 2022 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.)

Published
2022

27. [Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic hematopoietic stem cell transplantation in Philadelphia acute lymphoblastic leukemia].

Author

Galán Gómez V, de la Fuente Regaño L, Rodríguez Villa A, Díaz de Heredia Rubio C, González Vicent M, Badell Serra I, Fernández JM, Pascual Martínez AI, Pérez Hurtado JM, López Duarte M, Maldonado Regalado MS, and Pérez-Martínez A

Abstract

Introduction: Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT)., Patients and Methods: The role of allogeneic HSCT in Ph-ALL patients has been analysed through a multicentric study where data belonging to 70 patients diagnosed of this entity in different center that received HSCT between years 1998 and 2014, were reported by the Grupo Español de Trasplante Hematopoyético (GETH)., Results: The performance of HSCT from year 2004, in first complete remission (CR) status with thymoglobulin (ATG) based conditioning had a favorable impact on overall survival (OS). HSTC performance from year 2004, in first CR with ATG-based conditioning in addition to acute graft versus host disease (aGvHD) development, increased event free survival (EFS). Treatment with imatinib as well as undetectable minimal residual disease (MRD) prior to HSCT, combined with aGvHD, reduced risk of relapse (RR). Patient age less than 10 years when HSCT, first CR and ATG-based conditioning were associated to a lower transplant related mortality (TRM)., Conclusions: Patients that could achieve first CR that also received ATG-based conditioning had a better OS and EFS, so HSCT should be considered for this group of patients., (Copyright © 2021. Publicado por Elsevier España, S.L.U.)

Published
2021
Full Text
View/download PDF

28. Elevated levels of STAT1 in Fanconi anemia group A lymphoblasts correlate with the cells' sensitivity to DNA interstrand crosslinking drugs.

Author

Prieto-Remón I, Sánchez-Carrera D, López-Duarte M, Richard C, and Pipaón C

Subjects
Cell Line, Drug Resistance genetics, Enzyme Activation, Extracellular Signal-Regulated MAP Kinases metabolism, Fanconi Anemia Complementation Group A Protein deficiency, Fanconi Anemia Complementation Group A Protein genetics, Gene Expression, Humans, Interferon-gamma pharmacology, Phosphorylation drug effects, RNA Processing, Post-Transcriptional, STAT1 Transcription Factor metabolism, Transcription, Genetic, Tumor Necrosis Factor-alpha pharmacology, Cross-Linking Reagents toxicity, DNA Damage drug effects, Fanconi Anemia genetics, Fanconi Anemia metabolism, Lymphoid Progenitor Cells drug effects, Lymphoid Progenitor Cells metabolism, STAT1 Transcription Factor genetics
Abstract

Progressive bone marrow failure starting in the first decade of life is one of the main characteristics of Fanconi anemia. Along with the bone marrow failure, this pathology is characterized by congenital malformations, endocrine dysfunction and an extraordinary predisposition to develop cancer. The fact that hematopoietic progenitor cells from subjects with Fanconi anemia are sensitive to both DNA-interstrand crosslinking agents and inflammatory cytokines, which are aberrantly overproduced in these patients, has led to different explanations for the causes of the bone marrow failure. We analyzed STAT1 expression in lymphoblastoid cell lines derived from patients with Fanconi anemia group A and correlated this with aspects of the Fanconi anemia phenotype such as sensitivity to genotoxic agents or to inhibitory cytokines. We provide evidence of overexpression of STAT1 in FANCA-deficient cells which has both transcriptional and post-translational components, and is related to the constitutive activation of ERK in Fanconi anemia group A cells, since it can be reverted by treatment with U0126. STAT1 phosphorylation was not defective in the lymphoblasts, so these cells accumulated higher levels of active STAT1 in response to interferon gamma, probably in relation to their greater sensitivity to this cytokine. On the other hand, inhibition of STAT1 by genetic or chemical means reverted the hypersensitivity of Fanconi anemia group A lymphoblasts to DNA interstrand crosslinking agents. Our data provide an explanation for the mixed sensitivity of Fanconi anemia group A cells to both genotoxic stress and inflammatory cytokines and indicate new targets for the treatment of bone marrow failure in these patients.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results